Zydus receives final approval from USFDA for Nitroglycerin Sublingual Tablets; Stock up 1%

10 Mar 2022 , 10:50 AM

Zydus Lifesciences Ltd. has received final approval from the USFDA to market Nitroglycerin Sublingual Tablets in the strengths of 0.3 mg, 0.4mg and 0.6mg (US RLD: Nitrostat Sublingual Tablets).

Nitroglycerin Sublingual Tablets are used to relieve chest pain (angina) in people who have a certain heart condition (coronary artery disease). It may also be used before physical activities to help prevent chest pain. Nitroglycerin belongs to a class of drugs known as nitrates.

Angina occurs when the heart muscle is not getting enough blood. This drug works by relaxing and widening blood vessels so blood can flow more easily to the heart. The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 329 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

At around 10.54 am, Zydus Lifesciences Ltd was trading at Rs364.30 per piece up by Rs4.45 or 1.24% from its previous closing of Rs359.85 per piece on the BSE.